Date of AGM & Closing Date for Director Nominations
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASX Announcement
Date of AGM and Closing Date for
Director Nominations
5 October 2026
Racura Oncology Limited(“Racura” or the “Company”) advises, in accordance with ASXListing Rule 3.13.1,
that its Annual General Meeting is to be held at 12.00 noon AEDT on Monday, 23 November 2026 at the
Library Auditorium, State Library NSW, 1 Shakespeare Place, Sydney, New South Wales, Australia.
An item of business at the AGM will be the re-election and appointment of Directors. In accordance with
clause 15.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons
wishing to be considered for election as a Director is Monday, 12 October 2026.
Any nominations must be receivedby the Company in writing by no later than 5.00 pm AEDT on Monday,
12 October 2026.
– ENDS –
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily acts through G4-
DNA and RNA binding, resultingin potent silencingof MYC, an important regulatorof cancer growth. (E,E)-
bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety
profile. Recent Racuradiscoveries have enabledcomposition of matterIP filings that may provide 20 years
of patent protection over (E,E)-bisantrene.
Racura is advancing RC220, a proprietary formulation of (E,E)-bisantrene, to address significant unmet
needs across multiple oncology indications. Its clinical programs include a Phase 3 program in acute
myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small
cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program combining RC220 with doxorubicin, where
Racura aims to deliver both cardioprotection and enhanced anticancer activity for patients with solid
tumours.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of
Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
actively exploring partnerships, licence agreements and commercial merger and acquisition opportunities
to accelerate global access to RC220 for patients with cancer. Learn more at www.racuraoncology.com.
For questions about this announcement or previous Racura Oncology announcements, please visit our
Interactive Announcements page.
Racura encourages investors to go paperless by registeringtheir details with the Company’s share registry,
Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover